Mifflin Mark D, Betts Brent S, Frederick P Adam, Feuerman Jason M, Fenzl Carlton R, Moshirfar Majid, Zaugg Brian
Department of Ophthalmology and Visual Sciences, John A Moran Eye Center, University of Utah, Salt Lake City, UT.
The Eye Center, Huntsville, AL.
Clin Ophthalmol. 2017 Jun 12;11:1113-1118. doi: 10.2147/OPTH.S138272. eCollection 2017.
To compare the outcome of photorefractive keratectomy (PRK) and complications in patients treated with either loteprednol etabonate 0.5% gel or prednisolone acetate 1% suspension and fluorometholone (fml) 0.1% suspension.
John A Moran Eye Center, University of Utah, Salt Lake City, UT, USA.
Prospective, randomized, partially masked trial.
PRK was performed on 261 eyes of 132 participants. Patients were randomized to a postoperative corticosteroid regimen of either loteprednol etabonate 0.5% gel (loteprednol) or prednisolone 1% acetate suspension followed by fluorometholone 0.1% suspension (prednisolone/fml). Primary outcome measures included incidence and grade of postoperative corneal haze and incidence of increased intraocular pressure of 10 mmHg above baseline, or any intraocular pressure over 21 mmHg. Secondary outcome measures included uncorrected distance visual acuity, best corrected distance visual acuity, and manifest refraction spherical equivalent.
The incidence of haze in the first 3 months was 2.6% (3/114 eyes) in the loteprednol group and 4.8% (7/147 eyes) in the prednisolone/fml group and was not statistically significant between groups (=0.37). The incidence of elevated intraocular pressure was 1.8% (2/114 eyes) in the loteprednol group and 4.1% (6/147 eyes) in the prednisolone/fml group, and was not statistically significant between the groups (=0.12). The mean 3-month postoperative logMAR uncorrected visual acuity was -0.078±0.10 and -0.075±0.09 in the loteprednol and prednisolone/fml groups, respectively (=0.83).
Postoperative corneal haze and elevated intraocular pressure were uncommon in both treatment arms. There was no statistically significant difference between each postoperative regimen. Refractive results were similar and excellent in both treatment arms. A tapered prophylactic regimen of loteprednol 0.5% gel is equally effective to prednisolone 1%/fml 0.1% after PRK.
比较使用0.5%氯替泼诺醇酯凝胶、1%醋酸泼尼松龙混悬液和0.1%氟米龙(fml)混悬液治疗的患者进行准分子激光角膜切削术(PRK)的效果及并发症。
美国犹他州盐湖城犹他大学约翰·A·莫兰眼科中心。
前瞻性、随机、部分遮蔽试验。
对132名参与者的261只眼进行PRK。患者被随机分为术后使用0.5%氯替泼诺醇酯凝胶(氯替泼诺)或1%醋酸泼尼松龙混悬液随后使用0.1%氟米龙混悬液(泼尼松龙/fml)的皮质类固醇治疗方案。主要观察指标包括术后角膜 haze的发生率和分级以及眼压高于基线10 mmHg或任何眼压超过21 mmHg的发生率。次要观察指标包括未矫正远视力、最佳矫正远视力和明显屈光球镜等效度。
氯替泼诺组前3个月haze的发生率为2.6%(3/114只眼),泼尼松龙/fml组为4.8%(7/147只眼),两组间无统计学差异(P = 0.37)。氯替泼诺组眼压升高的发生率为1.8%(2/114只眼),泼尼松龙/fml组为4.1%(6/147只眼),两组间无统计学差异(P = 0.12)。氯替泼诺组和泼尼松龙/fml组术后3个月平均logMAR未矫正视力分别为-0.078±0.10和-0.075±0.09(P = 0.83)。
两个治疗组术后角膜haze和眼压升高均不常见。各术后治疗方案间无统计学显著差异。两个治疗组的屈光结果相似且良好。PRK后0.5%氯替泼诺醇酯凝胶的递减预防方案与1%泼尼松龙/0.1% fml同样有效。